ROBOSENSE
13.3.2021 03:32:07 CET | Business Wire | Press release
RoboSense ( https://robosense.ai/ ) announced the launch of China’s first automotive-grade solid-state LiDAR production line and would start mass production and delivery of the automotive-grade solid-state LiDAR RS-LiDAR-M1 for contract projects in Q2 this year.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210312005303/en/
At the CES2021 in January this year, RoboSense has officially unveiled the SOP version of the automotive-grade LiDAR RS-LiDAR-M1, which features a slim design, excellent performance, and reliable point cloud quality. Since July last year, the RS-LiDAR-M1 has successively received a number of orders for mass-production vehicle models around the world, among which, the first customer was an OEM from North America. In December last year, the RS-LiDAR-M1 samples were shipped to this OEM customer in batches, and became the world's first mass-production-ready automotive-grade MEMS solid-state LiDAR delivered.
Two days ago, Inceptio released the self-driving system "Xuanyuan" equipped with RoboSense solid-state LiDAR, and the two parties announced the partnership that the mass-produced L3 heavy-duty freight truck equipped with "Xuanyuan" system will be launched on the market by the end of 2021.
As a world-leading smart LiDAR supplier, RoboSense has reached in-depth cooperation with Inceptio from 2019 to provide high-performance automotive-grade MEMS solid-state LiDAR RS-LiDAR-M1 for Inceptio’s "Xuanyuan" system, the first full-stack self-developed autonomous trucking system for mass production. Inceptio develops the ULRS (ultra-long-range sensing), ARC (adaptive robust control) and FEAD (fuel-efficient autonomous driving) algorithms, and the ULRS can make the system perceive an ultra-long distance of up to 1,000 meters with a margin of error standing below 5%.
In June 2019, Inceptio has worked with Dongfeng Trucks and SINOTRUK respectively to developed L3 autonomous heavy-duty trucks. By the end of 2021, the mass-produced L3 heavy-duty trucks equipped with Inceptio’s "Xuanyuan" system with RoboSense LiDAR inside will be delivered to clients.
About RoboSense
Founded in 2014, RoboSense (Suteng Innovation Technology Co., Ltd.) is the leading provider of Smart LiDAR Sensor Systems incorporating LiDAR sensors, AI algorithms and IC chipsets, that transform conventional 3D LiDAR sensors to full data analysis and comprehension systems. Market-oriented, the company provides customers with various Smart LiDAR perception system solutions, including the MEMS and Mechanical types LiDAR HWs, fusion HW unit, and the AI-based fusion systems. To date, RoboSense LiDAR systems have been widely applied to the future mobility, including autonomous driving passenger cars, RoboTaxi, RoboTruck, RoboBus, automated logistics vehicles and intelligent road by domestic and international autonomous driving technology companies, OEMs, and Tier1 suppliers. https://robosense.ai/
About Inceptio
Inceptio Technology was founded in April 2018, with an aim to build a nation-wide freight network using autonomous driving trucks.
We focus on the transformation of line-haul logistics by providing a more secure, efficient, and economical Transportation-As-A-Service (Taas) to logistic customers. This is to be achieved with our automotive grade L3/L4 autonomous driving software/ hardware, developed in collaboration with major automotive manufacturers, fully integrated with mass-produced heavy-duty freight trucks. With our advanced technology and seasoned operation team, we envision to develop the most trustworthy autonomous freight service network.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210312005303/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom